|
 |
|||||||
 |
PRESS RELEASES CEOcast Features Biokeys Pharmaceuticals' CEO SAN DIEGO, California March 20, 2003 (PRIMEZONE) – Biokeys Pharmaceuticals, Inc. (OTCBB:BKYS) announced that an interview featuring Nicholas Jon Virca, the Company's Chief Executive Officer, is currently available on CEOcast http://www.ceocast.com (3/19/03) in real audio. In the interview, Mr. Virca discusses Biokeys Pharmaceuticals' HIV viral entry inhibitor, which is now being prepared for human clinical trials, the Company's HIV therapeutic vaccine, which it also plans to move into human testing later this year, and the Company's chemotherapy biomodulator that has been given approval for Phase II human trials in the US for metastatic colorectal cancer. About BKYS Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: Biokeys Pharmaceuticals Inc. Nicholas J.Virca, 858/271-9671 Fax: 8581/271-9678 virca@bkys.com |
